A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

Inclusion Criteria: * Patients with moderate to severe dysplasia and/or squamous carcinoma-in-situ of the oral cavity and/or oropharynx. * Patients with T1 squamous cell carcinoma of the oral cavity and/or oropharynx. * Patient may have primary and/or recurrent lesions to be treated. * Diagnosis must confirmed by biopsy. * Prior therapy of any type is allowed. * Male or female patients at least 18 years old. Female patients must not be pregnant and must be practicing a medically acceptable form of birth control, be sterile or post-menopausal. Male patients should be using a medically acceptable form of birth control or be sterile. * Patients must have an ECOG score of 0-2 (Appendix A 1 ). * Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure. Exclusion Criteria: * Patients with T2 or greater squamous cell carcinoma. * True tongue base lesions (as determined by the treating physician). * Patients with severe trismus that prevents adequate access to the lesion for treatment light delivery (as determined by the treating physician). * Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds. * Patients with impaired hepatic (alkaline phosphatase (hepatic) or SGOT;:3 times the upper normal limits). * Patients with minimal impairment of renal function (total serum bilirubin;: 2…